|
| Tip
of the Month: BioWorks™
3.2 |
|
 |
Keep your protein
databases in order and up to date. Protein sequences are
constantly added to databases and other sequences are
corrected. Maintaining and updating your databases will
improve the accuracy and validity of your database search
results. Bioworks 3.2 facilitates database management with our
FASTA Database tools including utilities to download
databases, index databases create new databases, edit
databases and create reversed databases. Furthermore, you can
now easily see exactly which database was used to generate a
search result, when the database was created, and how many
entries were in the database by looking at the Database
Information log file. |
| |
| Quantum Waves: Heated
Electrospray Ionization (H-ESI) Probe |
|
| The Ion Max™ compatible H-ESI probe from Thermo
Electron enhances LC-MS/MS assay sensitivity up to eight
times. "Dual Desolvation Zone" technology provides significant
advantages for demanding DMPK applications by optimizing the
extent of desolvation. The H-ESI probe is the most versatile
LC-MS/MS ion source technology available on the market today
and now comes standard on the Finnigan™ TSQ Quantum Ultra™. |
 |
| Watch the video to
learn more |
| Contribute to
Critical Mass |
|
 |
Critical Mass is
now accepting contributions from subscribers. If selected for
publication, contributors will receive a Thermo-branded
momento as a token of our appreciation. You are welcome to
send contributions in all areas of Mass Spectrometry. Critical
Mass will accept a range of contributions including but not
limited to Your Research Interests in Mass Spectrometry or
using Mass Spectrometry, Tips, New Applications, Interesting
Stories on using Thermo's Mass Spectrometers, etc. Please
click on the link provided below to read the Terms and
Conditions for making contributions. |
| Read Terms and
Conditions for Making
Contributions |
|
| Thermo at HUPO
2005 |
|
 |
| Thermo's Proteomicsⁿ workshop at HUPO 2005 will cover
solutions for protein quantitation, high-throughput protein
identification, PTM characterization, top-down analysis, and
biomarker discovery. A high-level summary will be followed by
detailed presentations describing the use of Thermo mass
spectrometers by two important contributors to the Human
Proteome Project, namely, Professors Chris Turck and Matthias
Mann, both from the Max Planck Institute. |
| Register
Now |
|
|
|
| Thermo Acquires
Ionalytics Corporation |
|
| Ionalytics Corporation is
a developer of a dynamic ion filtering device used with mass
spectrometers in bioanalysis, proteomics and drug discovery.
The company has developed a novel ion separation tool based on
patent-protected FAIMS (High-Field Asymmetric Waveform Ion
Mobility Spectrometry) technology. FAIMS will contribute
tremendously to a customer's ability to push their detection
limits, which is critical to accelerate drug discovery
research. |
| Read the Press
Release |
| Do Biologists Really
Need Mass Spectrometry? |
|
| Life science research has
harnessed the power of mass spectrometry to gain a fundamental
understanding of biology. With the continuous, rapid
development of ionization methods and detector technologies
over the past 30 years, mass spectrometry has proved its value
and migrated inexorably from dedicated core facilities into
biology labs and to the forefront of contemporary biology
research. |
 |
| Read Full
Article |
| Software: Mass
Frontier™
4.0 |
|
 |
Mass Frontier 4.0
provides you with the tools required to transform mass
spectral data into results - fast! The new Mass Frontier
excels at predictive fragmentation and data management. Mass
Frontier provides a mechanistic understanding of fragmentation
schemes using proprietary mass spectral interpretation
algorithms. In addition, relationships within datasets can be
explored using various types of classification such as PCA,
neural networks and fuzzy clustering. |
| More
Information |
| Trap Talk: Data
Dependent™ Constant Neutral Loss
Scans |
|
| In vitro biotransformation
studies are commonly performed in the early drug discovery
stage to determine the metabolic pathways and to generate
Phase I and Phase II metabolites for their further
characterization, both of which typically show a
characteristic mass shift with respect to the molecular ion of
the parent compound. The wide variety of potential metabolites
and resulting complex mixtures make their identification a
challenging and labor-intensive task. |
 |
| Read Full Article
(PDF 127 kB) |
|
|
|
|
|
|
 |
|
|
|
